DE69033200D1 - Wundbehandlung mittels biologisch aktiver peptide - Google Patents

Wundbehandlung mittels biologisch aktiver peptide

Info

Publication number
DE69033200D1
DE69033200D1 DE69033200T DE69033200T DE69033200D1 DE 69033200 D1 DE69033200 D1 DE 69033200D1 DE 69033200 T DE69033200 T DE 69033200T DE 69033200 T DE69033200 T DE 69033200T DE 69033200 D1 DE69033200 D1 DE 69033200D1
Authority
DE
Germany
Prior art keywords
biologically active
wound treatment
active peptides
wound
host
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69033200T
Other languages
English (en)
Other versions
DE69033200T2 (de
Inventor
Barry Berkowitz
Leonard Jacob
Michael Zasloff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Magainin Pharmaceuticals Inc
Original Assignee
Magainin Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magainin Sciences Inc filed Critical Magainin Sciences Inc
Application granted granted Critical
Publication of DE69033200D1 publication Critical patent/DE69033200D1/de
Publication of DE69033200T2 publication Critical patent/DE69033200T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
DE69033200T 1989-12-18 1990-12-12 Wundbehandlung mittels biologisch aktiver peptide Expired - Fee Related DE69033200T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/451,777 US5045531A (en) 1989-12-18 1989-12-18 Wound treatment employing biologically active ion channel forming peptides and proteins
PCT/US1990/007440 WO1991008758A1 (en) 1989-12-18 1990-12-12 Wound treatment employing biologically active peptides

Publications (2)

Publication Number Publication Date
DE69033200D1 true DE69033200D1 (de) 1999-08-12
DE69033200T2 DE69033200T2 (de) 2000-02-24

Family

ID=23793638

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69033200T Expired - Fee Related DE69033200T2 (de) 1989-12-18 1990-12-12 Wundbehandlung mittels biologisch aktiver peptide

Country Status (10)

Country Link
US (2) US5045531A (de)
EP (1) EP0505497B1 (de)
JP (1) JPH05504566A (de)
AT (1) ATE181835T1 (de)
CA (1) CA2032059C (de)
DE (1) DE69033200T2 (de)
DK (1) DK0505497T3 (de)
ES (1) ES2136599T3 (de)
GR (1) GR3031459T3 (de)
WO (1) WO1991008758A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000194A1 (en) * 1987-07-06 1989-01-12 Louisiana State University Agricultural And Mechan Inhibition of eucaryotic pathogens and neoplasms and stimulation of fibroblasts and lymphocytes with lytic peptides
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
CA1327311C (en) * 1987-07-06 1994-03-01 Jesse M. Jaynes Therapeutic antimicrobial polypeptides, their use and methods for preparation
US5912231A (en) * 1989-07-07 1999-06-15 Scripps Clinic And Research Foundation Substitution analogues of magainin peptides
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
NZ237202A (en) * 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
AU648140B2 (en) * 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
EP0671930A4 (de) * 1991-07-25 1996-02-07 Magainin Pharma Prophylaxe und behandlung der gesundheitlichen schädigung der zahnhygiene durch biologisch aktive peptide.
WO1994001451A2 (en) * 1992-07-13 1994-01-20 Bionebraska, Inc. Method for modification of recombinant polypeptides
US5656456A (en) * 1992-07-13 1997-08-12 Bionebraska, Inc. Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof
US5593866A (en) * 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
AU6251594A (en) * 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Treatment of cancerous growths with biologically active peptides and protease inhibitors
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5561107A (en) * 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
US5968904A (en) * 1993-06-04 1999-10-19 Demegen, Inc. Modified arginine containing lytic peptides and method of making the same by glyoxylation
US5856178A (en) * 1993-08-30 1999-01-05 Utah State University DNA cassettes for expression of lytic peptides in mammalian cells and transgenic organisms containing same
WO1995011670A1 (en) * 1993-10-25 1995-05-04 The Liposome Company, Inc. Liposomal defensins
WO1995013085A1 (en) 1993-11-08 1995-05-18 Demeter Biotechnologies Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
US6057291A (en) 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
FR2735983B1 (fr) * 1995-06-29 1997-12-05 Centre Nat Rech Scient Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal
JP3860838B2 (ja) 1995-08-23 2006-12-20 ユニバーシティー オブ ブリティッシュ コロンビア 抗微生物性陽イオン性ペプチドおよびそのスクリーニング方法
US6077826A (en) * 1996-01-25 2000-06-20 Kansas State University Research Foundation Synthetic macromolecular channel assembly for transport of chloride ions through epithelium useful in treating cystic fibrosis
WO1997039764A1 (fr) * 1996-04-23 1997-10-30 Toray Industries, Inc. Agent anti-pylori
DE10051983A1 (de) * 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
WO2005094423A2 (en) * 2004-02-26 2005-10-13 President And Fellows Of Harvard College Selective inhibition of proteasomes of tuberculosis and other bacteria
WO2009070564A2 (en) * 2007-11-27 2009-06-04 Macrochem Corporation Compositions and methods for prevention of infection in transcutaneous osseointegrated implants
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507230A (en) * 1982-05-12 1985-03-26 Research Corporation Peptide synthesis reagents and method of use
US4863899A (en) * 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4810777A (en) * 1987-03-04 1989-03-07 The United States Of America As Represented By The Department Of Health And Human Services Antimicrobial compounds
EP0346429B1 (de) * 1987-12-24 1994-12-28 Gropep Pty. Ltd. Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2)
US4962277A (en) * 1988-12-09 1990-10-09 Scripps Clinic And Research Foundation Deletion analogues of magainin peptides
US5073542A (en) * 1989-06-07 1991-12-17 Magainin Sciences Inc. CPF peptide compositions and their use in inhibiting growth of target cells or a virus

Also Published As

Publication number Publication date
JPH05504566A (ja) 1993-07-15
US5045531A (en) 1991-09-03
EP0505497A4 (en) 1993-09-08
GR3031459T3 (en) 2000-01-31
CA2032059A1 (en) 1991-06-19
CA2032059C (en) 2003-02-25
WO1991008758A1 (en) 1991-06-27
DE69033200T2 (de) 2000-02-24
EP0505497B1 (de) 1999-07-07
USRE35492E (en) 1997-04-08
ATE181835T1 (de) 1999-07-15
ES2136599T3 (es) 1999-12-01
DK0505497T3 (da) 1999-11-22
EP0505497A1 (de) 1992-09-30

Similar Documents

Publication Publication Date Title
DE69033200D1 (de) Wundbehandlung mittels biologisch aktiver peptide
ES2196640T3 (es) Dispositivo terapeutico transdermico con capsaicina y analogos de capsaicina.
ES2186693T3 (es) Uso combinado del acido hialuronico y de agentes terapeuticos para mejorar el efecto terapeutico.
GEP20002146B (en) Therapeutic Peptide Derivatives
DE69010336D1 (de) Pharmazeutische zusammensetzung zum abnehmen.
ES2043890T3 (es) Nuevo uso medico.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
SE8902638L (sv) Stabiliserade protein- eller peptidkonjugat
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
MX9402339A (es) Formulacion de proteina.
ID17768A (id) Metoda pengobatan
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
RU95106651A (ru) Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE103804T1 (de) Pharmazeutische praeparate.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
ATE107170T1 (de) Zusammensetzung und behandelung mittels biologisch aktiven peptiden und bestimmten anionen.
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
RU94044795A (ru) Способ лечения невралгии тройничного нерва
RU95102184A (ru) Способ лечения синдрома после тотальной оварэктомии
NO911470L (no) Sammensetning og behandling med biologisk aktive peptiderog visse anioner.
RU95106400A (ru) Способ предупреждения и лечения дифтерийных нейропатий в эксперименте
RU94045317A (ru) Способ лечения вилюйского энцефаломиелита

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MAGAININ PHARMACEUTICALS,INC., PLYMOUTH MEETING, P

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee